- Home
- AACG vs BNR Comparison
AACG vs BNR Comparison
Compare AACG & BNR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AACG
- BNR
- Stock Information
- Founded
- AACG 1999
- BNR 2014
- Country
- AACG China
- BNR China
- Employees
- AACG N/A
- BNR N/A
- Industry
- AACG Other Consumer Services
- BNR Medical Specialities
- Sector
- AACG Real Estate
- BNR Health Care
- Exchange
- AACG Nasdaq
- BNR Nasdaq
- Market Cap
- AACG 24.4M
- BNR 29.1M
- IPO Year
- AACG N/A
- BNR 2020
- Fundamental
- Price
- AACG $0.89
- BNR $4.22
- Analyst Decision
- AACG
- BNR
- Analyst Count
- AACG 0
- BNR 0
- Target Price
- AACG N/A
- BNR N/A
- AVG Volume (30 Days)
- AACG 13.5K
- BNR 29.7K
- Earning Date
- AACG 08-06-2025
- BNR 08-21-2025
- Dividend Yield
- AACG N/A
- BNR N/A
- EPS Growth
- AACG N/A
- BNR N/A
- EPS
- AACG N/A
- BNR N/A
- Revenue
- AACG $37,997,003.00
- BNR $72,112,038.00
- Revenue This Year
- AACG N/A
- BNR $136.32
- Revenue Next Year
- AACG N/A
- BNR N/A
- P/E Ratio
- AACG N/A
- BNR N/A
- Revenue Growth
- AACG 21.24
- BNR 0.53
- 52 Week Low
- AACG $0.50
- BNR $2.18
- 52 Week High
- AACG $1.10
- BNR $7.90
- Technical
- Relative Strength Index (RSI)
- AACG 54.01
- BNR 63.77
- Support Level
- AACG $0.83
- BNR $3.06
- Resistance Level
- AACG $0.80
- BNR $3.50
- Average True Range (ATR)
- AACG 0.04
- BNR 0.21
- MACD
- AACG 0.01
- BNR 0.05
- Stochastic Oscillator
- AACG 69.25
- BNR 95.65
About AACG ATA Creativity Global
ATA Creativity Global is an international educational services company focused on providing quality learning experiences that cultivate and enhance students' creativity. The operating segments of the company are (i) Overseas art study services (ii) Other educational services and (iii) Other services. Majority of its revenue comes from Overseas art study services.
About BNR Burning Rock Biotech Limited
Burning Rock Biotech Ltd is a cancer diagnostics company. It is a NGS-based cancer therapy selection company. Its cancer therapy selection platform is built upon advanced proprietary technologies, comprehensive portfolio of products and a two-pronged market-driven commercial infrastructure addressing both larger hospitals through our in-hospital model and smaller hospitals through our central laboratory model. It had three operating segments, including Central laboratory business, In-hospital business and Pharma research and development services. It generates the majority of its revenue from Central laboratory business. Its products are Pan-HEME, OncoScreen-WES, brPROPHET, OncoScreen Plus, and others.